HealthdirectFree Australian health advice you can count on.

• Patients with a past history of hepatitis B virus infection should be carefully monitored for signs of fulminant hepatitis or liver damage.‍​‍‍‍​‍‍‍‍‍‍‍‍​‍ Lab values must be checked during and after the treatment with obinutuzumab as there is a possibility of reactivation of the hepatitis B virus. • Discontinue the treatment with obinutuzumab and provide appropriate medical care, if hypersensitivity reactions such as breathing difficulty, low blood pressure, and serum sickness occur. • Patients should be monitored regularly for the counts of neutrophils and platelets along with any symptoms or signs of infections such as fever and cough. • Symptoms of tumor lysis syndrome that include nausea, loose stools, vomiting, and weakness can occur during the treatment with obinutuzumab. Patients must be provided with proper supportive care by correcting water-electrolyte imbalance and monitoring the kidney function regularly. • Patients must be monitored for any neurological changes such as confusion, dizziness, and loss of balance that could be symptoms of progressive multifocal leukoencephalopathy (PML) by performing brain MRI scan and lumbar puncture. The obinutuzumab dose can be reduced or the treatment can be discontinued based on the condition of the patient who develops PML.